This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01595854
First received: May 9, 2012
Last updated: June 18, 2013
Last verified: June 2013
  Purpose
Evaluation of potential ticagrelor effects on dabigatran exposure and evaluation of two new pharmacodynamic methods

Condition Intervention Phase
Healthy Drug: dabigatran etexilate Drug: Ticagrelor Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor (Part 1 and 2, Open, Non-randomised, 2 Parallel Groups) and Assessment of Ticagrelor Interaction Potential With Dabigatran (Part 3, Open, Randomised, Two-period Cross-over) in Healthy Male Subjects

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞) [ Time Frame: -1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours ]
    Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran.

  • Total Dabigatran: Maximum Measured Concentration (Cmax) [ Time Frame: -1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours ]
    Maximum measured concentration of total dabigatran in plasma, per period.


Secondary Outcome Measures:
  • Number of Participants With Drug Related Adverse Events [ Time Frame: From screening until the end-of-study examination ]
    The number of participants with drug related adverse events


Enrollment: 36
Study Start Date: May 2012
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Test 2 (part 3)
low dose dabigatran + high dose ticagrelor
Drug: Ticagrelor
high dose ticagrelor
Drug: dabigatran etexilate
medium dose dabigatran
Active Comparator: Test 1 (part 1 + 2)
high dose ticagrelor
Drug: Ticagrelor
high dose ticagrelor
Experimental: Reference 1 (part 1 + 2)
medium dose dabigatran
Drug: dabigatran etexilate
medium dose dabigatran
Experimental: Reference 2 (part 3)
low dose dabigatran
Drug: dabigatran etexilate
low dose dabigatran

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  1. Healthy male subjects

    Exclusion criteria:

  2. Any relevant deviation from healthy conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01595854

Locations
Germany
1160.141.1 Boehringer Ingelheim Investigational Site
Biberach, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01595854     History of Changes
Other Study ID Numbers: 1160.141
2012-000874-42 ( EudraCT Number: EudraCT )
Study First Received: May 9, 2012
Results First Received: June 18, 2013
Last Updated: June 18, 2013

Additional relevant MeSH terms:
Ticagrelor
Dabigatran
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Anticoagulants

ClinicalTrials.gov processed this record on July 21, 2017